Search results for "CELL PROLIFERATION"

showing 10 items of 1056 documents

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.

2013

The identification of prognostic markers has clinical implications in epithelial ovarian carcinoma (EOC). Here, we studied markers for proliferation (Ki-67), endocrine regulation [progesterone receptor (PR), estrogen receptor (ER)], and invasion [urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1)]. All patients with available follow-up information and EOC tissue, who were treated at our institution between 1997 and 2004, were enrolled in the present study. Expression of Ki-67, PR and ER was determined by immunohistochemical analyses. uPA and PAI-1 antigen levels were determined using enzyme‑linked immunosorbent assays. One hundred and eight patients enter…

OncologyCancer Researchmedicine.medical_specialtyCarcinoma Ovarian EpithelialDisease-Free SurvivalCohort StudiesInternal medicineProgesterone receptorPlasminogen Activator Inhibitor 1medicineBiomarkers TumorHumansNeoplasms Glandular and EpithelialProspective cohort studyCell ProliferationRetrospective StudiesUrokinaseOvarian Neoplasmsbiologybusiness.industryProportional hazards modelHazard ratioCancerGeneral MedicineMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorTumor BurdenKi-67 AntigenOncologyReceptors EstrogenKi-67biology.proteinFemalebusinessOvarian cancerReceptors Progesteronemedicine.drugOncology reports
researchProduct

Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis

2008

Abstract Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of life. There is no robust evidence that ESAs, when used as indicated, have a negative effect…

OncologyCancer Researchmedicine.medical_specialtyPathologyAnemiaCellHemoglobinsNeoplasmsInternal medicinemedicineHumansErythropoietinCell ProliferationTumor hypoxiabusiness.industryAnemiaCell DifferentiationHypoxia (medical)Tumor OxygenationHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseasePhenotypeCell HypoxiaRecombinant ProteinsOxygenCell Transformation Neoplasticmedicine.anatomical_structureOncologyHematinicsHemoglobinmedicine.symptombusinessPerfusionThe Oncologist
researchProduct

Tumorigenic and metastatic activity of human thyroid cancer stem cells

2010

Abstract Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDHhigh) activity and unlimited replication potential. ALDHhigh cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by…

OncologyMaleCancer ResearchLung NeoplasmsPapillaryNudeMessengerThyroid GlandFluorescent Antibody TechniqueTYROSINE KINASEMice SCIDCell TransformationImmunoenzyme TechniquesMiceMice Inbred NODCell MovementAdenocarcinoma FollicularThyroid cancerRADIOACTIVE IODINETumor Stem Cell AssayEPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE-ACTIVITY; ACUTE MYELOID-LEUKEMIA; RADIOACTIVE IODINE; TYROSINE KINASE; LUNG-CANCER; CARCINOMA; RECEPTOR; GROWTH; DIFFERENTIATIONBlottingReverse Transcriptase Polymerase Chain ReactionThyroidMiddle AgedProto-Oncogene Proteins c-metFlow CytometryEPITHELIAL-MESENCHYMAL TRANSITIONmedicine.anatomical_structureCell Transformation NeoplasticDIFFERENTIATIONOncologyNeoplastic Stem CellsAdenocarcinomaGROWTHFemaleStem cellWesternAdultmedicine.medical_specialtyBlotting WesternMice NudeACUTE MYELOID-LEUKEMIABiologyAdenocarcinomaSCIDALDEHYDE DEHYDROGENASE-ACTIVITYThyroid carcinomaYoung AdultLUNG-CANCERAdenocarcinoma Follicular; Adult; Aged; Aldehyde Dehydrogenase; Animals; Blotting Western; Carcinoma; Carcinoma Papillary; Case-Control Studies; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Transformation Neoplastic; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice Inbred NOD; Mice Nude; Mice SCID; Middle Aged; Neoplasm Invasiveness; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA Messenger; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Gland; Thyroid Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays; Young Adult; Cancer Research; OncologyCancer stem cellSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineCell AdhesionAnimalsHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsALDH Human Thyroid Cancer Stem CellsAgedCell ProliferationNeoplasticRECEPTORCarcinomaFollicularTumor Stem Cell AssayCancerAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysCarcinoma PapillaryCase-Control StudiesInbred NODRNAProto-Oncogene Proteins c-akt
researchProduct

Epulis-Like Presentation of Gingival Renal Cancer Metastasis

2017

Mouth metastatic cancers are very rare and they usually represent the evidence of a widespread disease. Common primary tumors are lung carcinoma in men and breast carcinoma in women, followed by kidney cancer. In the oral soft tissues, the gingiva is the most common site, suggesting a possible role of inflammation in the attraction of circulating tumor cells. Oral metastasis has a serious prognosis. In this work, we describe the case of a 58-year-old man affected by renal cancer, who was brought to our attention for the appearance of a gingival swelling. Initially, the lesion was excised through a provisional clinical diagnosis of epulis. Subsequently, anatomopathological analysis showed a …

OncologyPathologymedicine.medical_specialtyEpulisOphtalmologieCase Reportlcsh:RC254-282MetastasisMetastasis03 medical and health sciences0302 clinical medicineCirculating tumor cellClear-cell adenocarcinomaInternal medicineCarcinomamedicineClear-cell adenocarcinomaRiñones -- CáncerCell proliferationbusiness.industryOral cancerCancerMetástasisKidney cancer030206 dentistryCáncerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBoca -- CáncerOncology030220 oncology & carcinogenesisbusinessBreast carcinomaKidney cancer
researchProduct

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

2015

Abstract Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future…

Oncologymedicine.medical_specialtyInternational CooperationImmunologyMEDLINEMedical OncologyBiochemistryMyeloproliferative DisordersSurveys and QuestionnairesInternal medicinehemic and lymphatic diseasesmedicineHumansResponse criteriaCell ProliferationClinical Trials as TopicMyeloproliferative DisordersAdult patientsSurrogate endpointbusiness.industryStandard treatmentMyelodysplastic syndromesfood and beveragesCell BiologyHematologymedicine.diseaseClinical trialPhenotypeTreatment OutcomeHematologic NeoplasmsMyelodysplastic SyndromesMutationPractice Guidelines as TopicDisease ProgressionPhysical therapybusinessAlgorithmsPerspectives
researchProduct

Towards an ontogenetic understanding of inflorescence diversity

2013

Backgrounds and aims Conceptual and terminological conflicts in inflorescence morphology indicate a lack of understanding of the phenotypic diversity of inflorescences. In this study, an ontogeny-based inflorescence concept is presented considering different meristem types and developmental pathways. By going back to the ontogenetic origin, diversity is reduced to a limited number of types and terms. Methods Species from 105 genera in 52 angiosperm families are investigated to identify their specific reproductive meristems and developmental pathways. Based on these studies, long-term experience with inflorescences and literature research, a conceptual framework for the understanding of infl…

OntogenyMeristemArticlesBiodiversityPlant ScienceBiologyMeristemMagnoliopsidaInflorescenceRacemeBotanyPrimordiumInflorescenceLeafySensu strictoCell ProliferationPanicleAnnals of Botany
researchProduct

New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one?

2014

A series of mono- and heterodinuclear gold(I) and platinum(II) complexes with a new bipyridylamine-phosphine ligand have been synthesized and characterized. The X-ray structures of the ligand precursor 4-iodo-N,N-di(pyridin-2-yl)benzamide, and of one gold derivative are reported. All the complexes display antiproliferative properties in vitro in human cancer cells in the range of cisplatin or higher, which appear to correlate with compounds' uptake. Interestingly, studies of the interactions of the compounds with models of DNA indicate different mechanisms of actions with respect to cisplatin. The biological activity study of these complexes provides useful information about the interest of…

Organoplatinum CompoundsStereochemistryCell SurvivalPhosphinesPyridinesthioglucoseGOLD COMPOUNDSchemistry.chemical_elementAntineoplastic AgentsPLATINUM COMPLEXESBiochemistryRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipGold CompoundsCoordination ComplexesCell Line TumormedicineHumansDNA bindingBenzamideBIOLOGICAL-PROPERTIESCell ProliferationCisplatinheteronuclear complexDERIVATIVESChemistryLigandCytotoxinsBiological activityBiological TransportDNAPYRIDINEanticancer agentRutheniumHeteronuclear moleculepolymerizationBenzamidesLIGANDSCisplatinGold complexesPlatinumOrganogold Compoundsmedicine.drugPlasmidsJournal of inorganic biochemistry
researchProduct

cis-Dichloroplatinum(II) complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-ones: Synthesis and cytotoxicity in human cancer cell lines in vitro

2013

A novel family of cisplatin-type complexes tethered to dibenzo[c,h][1,6]naphthyridin-6-one topoisomerase inhibitor via a polymethylene chain and their nonplatinated counterparts were prepared. Their potential cytotoxicity was assessed in three human colorectal cancer cell lines HCT 116, SW480 and HT-29 and compared to the reference molecules cisplatin and oxaliplatin. Platinated compounds were poorly active whilst nonplatinated dibenzo[c,h][1,6]naphthyridin-6-one moieties exhibited higher cytotoxic properties than cisplatin and oxaliplatin whatever the length of the polymethylene chain; molecules containing the tri- and hexamethylene chain length were the most cytotoxic.

Organoplatinum Compoundsmedicine.drug_classStereochemistryAntineoplastic AgentsStructure-Activity RelationshipCell Line TumorDrug DiscoverymedicineHumansCytotoxic T cellMoleculeNaphthyridinesCytotoxicityCell ProliferationPharmacologyCisplatinDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryGeneral MedicineHCT116 CellsIn vitroOxaliplatinCell cultureDrug Screening Assays AntitumorHT29 CellsTopoisomerase inhibitormedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

The role of the dentist in the diagnosis and management of patients with oral mucosal diseases

2021

Based on a few case reports of oral mucosal diseases a number of questions is raised about the role of dentists-general practitioners in the diagnostic procedure and management of patients with such diseases. For instance, are dentists prepared to prescribe topical corticosteroids and should dentists be taught how and when to take a biopsy? And how about palpation of the neck? A strong recommendation is made to take clinical pictures for proper documentation and, if needed, for telediagnostic procedures. Another issue relates to the communication between dentists and dental specialists when dealing with patients with oral diseases. In case of a patient suffering from burning mouth syndrome …

Orofacial painmedicine.medical_specialtyDentistsMEDLINEReviewBurning Mouth SyndromePalpationcapsaicinoral epithelial dysplasiaFacial PainBiopsymedicineHumansGeneral DentistryUNESCO:CIENCIAS MÉDICASMaxillofacial surgeonsOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryGeneral surgeryapoptosischiliBurning mouth syndromeoral cancerstomatognathic diseasescell proliferationOtorhinolaryngologySurgerymedicine.symptombusinessMouth DiseasesMedicina oral patologia oral y cirugia bucal
researchProduct